|
MYSM1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.95019999833002E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.42609999995858E-07 |
| Normal-vs-Stage2 |
2.67570000045403E-07 |
| Normal-vs-Stage3 |
2.48770000155218E-08 |
| Normal-vs-Stage4 |
2.63149999568668E-08 |
| Stage1-vs-Stage2 |
2.023400E-01 |
| Stage1-vs-Stage3 |
7.610100E-02 |
| Stage1-vs-Stage4 |
5.201900E-02 |
| Stage2-vs-Stage3 |
9.740600E-01 |
| Stage2-vs-Stage4 |
7.861000E-01 |
| Stage3-vs-Stage4 |
7.909200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.75050000050803E-07 |
| Normal-vs-AfricanAmerican |
7.642300E-03 |
| Normal-vs-Asian |
1.53540000003005E-06 |
| Caucasian-vs-AfricanAmerican |
2.993600E-01 |
| Caucasian-vs-Asian |
8.178800E-01 |
| AfricanAmerican-vs-Asian |
2.776600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.40629999867414E-08 |
| Normal-vs-Female |
2.42479999967848E-07 |
| Male-vs-Female |
1.090170E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.67399999995155E-06 |
| Normal-vs-Age(41-60Yrs) |
2.76430001111549E-09 |
| Normal-vs-Age(61-80Yrs) |
1.66579999794081E-08 |
| Normal-vs-Age(81-100Yrs) |
2.15289999999646E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.344400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.649700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.260620E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.842000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.785200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.264000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.358470E-03 |
| Classical-VS-Follicular |
3.653900E-02 |
| Classical-VS-Other |
1.783590E-01 |
| Classical-VS-Normal |
2.1063999999793E-06 |
| Tall-VS-Follicular |
2.875800E-01 |
| Tall-VS-Other |
8.417400E-01 |
| Tall-VS-Normal |
2.98049995794969E-09 |
| Follicular-VS-Other |
5.703000E-01 |
| Follicular-VS-Normal |
1.18740000054629E-08 |
| Other-VS-Normal |
3.898000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.57030000511338E-08 |
| Normal-vs-N1 |
3.796300E-04 |
| N0-vs-N1 |
1.177570E-01 |
|
|
